The C5 inhibitor eculizumab resulted in recovery and reduced mean CRP levels in four patients with COVID-19 [92], although the global Phase 3 clinical trial evaluating the longer-acting C5 inhibitor ravulizumab was recently discontinued for lack of efficacy [94]. Here, C5 is linked to COVID-19.